AnaptysBio Q2 net loss narrows to $38.6M; rosnilimab Phase 2b RA data positive

ANAPTYSBIO, INC

2025-Q2 EPS reported -$2.62 vs consensus -$1.57 ▼ miss (-66.6%)

Net loss $38.6M ($1.34/sh) vs $46.7M ($1.71) YoY; collaboration revenue $22.3M, up from $11.0M.
Cash & investments $293.7M as of June 30, 2025; cash runway through year-end 2027 reiterated.
Rosnilimab RA Phase 2b shows JAK-like efficacy, durable off-drug response; UC Phase 2 enrollment complete, top-line Q4 2025.
ANB033 (CD122 antagonist) to begin Phase 1b in celiac disease by Q4 2025; R&D event planned.
Anticipate $75M GSK milestone in 2025 once Jemperli achieves $1B annual net sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.